Invention Grant
- Patent Title: Treatment regimens using anti-NKG2A antibodies
-
Application No.: US15511792Application Date: 2015-09-15
-
Publication No.: US10676523B2Publication Date: 2020-06-09
- Inventor: Pascale Andre , Mathieu Blery , Carine Paturel , Caroline Soulas , Nicolaï Wagtmann
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: Saliwanchik, Lloyd & Eisenschenk
- International Application: PCT/EP2015/071073 WO 20150915
- International Announcement: WO2016/041947 WO 20160324
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; C07K16/30 ; A61K39/00
Abstract:
The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
Public/Granted literature
- US20170298131A1 TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES Public/Granted day:2017-10-19
Information query
